Sugi Predict

Sugi Predict / Compounds / SCHEMBL30350331

SCHEMBL30350331

SCHEMBL30350331

N#Cc1csc2c(F)cccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.39
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CUL4A Q13619 1/20 0.34
▸ BCAT1 P54687 1/20 0.34
▸ DYRK1A Q13627 3/20 0.33
▸ TRPV4 Q9HBA0 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ PGR P06401 1/20 0.32
▸ AR P10275 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ IMPDH2 P12268 1/20 0.32
▸ IMPDH1 P20839 1/20 0.32
▸ CYP11B1 P15538 1/20 0.31
▸ CYP11B2 P19099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29153598 1.00 CYP2A6 (0.39) CYP2A6CA1CA2CUL4ABCAT1
Trifluoroacetic Acid SCHEMBL30350348 0.87 SLC22A12 (0.33) CYP2A6ALDH1A1MEN1KMT2AL3MBTL1
Trifluoroacetic Acid SCHEMBL30319487 0.87 SLC22A12 (0.33) CYP2A6ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL29915143 0.78 DYRK1A (0.46) CYP2A6CA1CA2DYRK1AALDH1A1
SCHEMBL27002564 0.78 DYRK1A (0.46) CYP2A6CA1CA2DYRK1AALDH1A1
SCHEMBL10693338 0.78 TSHR (0.45) CYP2A6CA1CA2DYRK1AALDH1A1
SCHEMBL31152165 0.74 CYP2A6 (0.39) CYP2A6TRPV4
SCHEMBL10692169 0.74 CYP2A6 (0.36) CYP2A6CA1CA2DYRK1AALDH1A1
SCHEMBL12281175 0.74 CYP2A6 (0.40) CYP2A6CA1CA2DYRK1AALDH1A1
SCHEMBL31208601 0.73 PDE4B (0.36) CYP2A6CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118974055-A Quinazoline compounds as inhibitors of mutant KRAS proteins and uses thereof 美国安进公司 2024-11-15 — — CN claimed
WO-2026101924-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
CN-122029167-A Condensed heteroaryl compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2026-05-12 — — CN disclosed
EP-4724445-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF Kumquat Biosciences Inc. (US) 2026-04-15 — — EP disclosed
US-12600733-B2 KRAS inhibitors ELI LILLY AND COMPANY (US) 2026-04-14 — — US disclosed
US-20260092075-A1 KRAS INHIBITORS LILLY CO ELI (US) 2026-04-02 — — US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
WO-2025226775-A2 COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES NEW YORK UNIVERSITY (US) 2025-10-30 — — WO disclosed
EP-4640684-A1 KRAS G12D INHIBITORS AND USES THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-10-29 — — EP disclosed
WO-2024041573-A1 FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF ZAI LAB (SHANGHAI) CO., LTD. (CN) 2024-02-29 — — WO disclosed
WO-2024031088-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2024-02-08 — — WO disclosed
CN-117500799-A Substituted fused azines as KRAS G12D inhibitors 伊莱利利公司 2024-02-02 — — CN disclosed
CN-117327103-A Substituted pyrimido ring inhibitor and preparation method and application thereof 苏州泽璟生物制药股份有限公司 2024-01-02 — — CN disclosed
CN-117157290-A Compositions and methods for inhibiting KRAS 瑟拉斯有限公司 2023-12-01 — — CN disclosed
WO-2023215802-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-11-09 — — WO disclosed
WO-2023172737-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-09-14 — — WO disclosed
CN-116199703-A Fused tetracyclic heterocyclic compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2023-06-02 — — CN disclosed
WO-2023066371-A1 NITROGEN-CONTAINING TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2023-04-27 — — WO disclosed
WO-2023061294-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 再鼎医药(上海)有限公司 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600733-B2 KRAS inhibitors KRAS, NRAS, HRAS CYP2A6 2697/4885CA1 3532/4885CA2 2768/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS CYP2A6 3387/4885CA1 4864/4885CA2 4491/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS CYP2A6 3387/4885CA1 4864/4885CA2 4491/4885
US-20260092075-A1 KRAS INHIBITORS KRAS, NRAS, HRAS CYP2A6 2416/4885CA1 2858/4885CA2 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.